Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary ...

Preliminary neffy net product revenue for the fourth quarter of 2024 was approximately $6.5 million, with total net product ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shares gapped up before the market opened on Tuesday after Raymond James raised their price target on the stock from $26.00 to $28.00. The ...

The licensing deal includes substantial upfront and milestone payments. ARS Pharma is also exploring using its intranasal epinephrine technology for treating chronic urticaria, with a Phase 2b ...

neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). In November 2024, ARS Pharma announced ...

“For ARS Pharma, 2024 marked a pivotal year, securing regulatory approvals for neffy as the first and only intranasal epinephrine treatment, laying a solid foundation for our commercial success ...

and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis can ...

neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). In November 2024, ARS Pharma ...

and CEO of ARS Pharma.“ neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis ...

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA ...